European Journal of Dermatology
MENUA phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs Volume 27, numéro 3, May-June 2017
Auteurs
Background
5 Division of Dermatology and Dermato-Oncology,
Department of Dermatology,
Medical University of Vienna,
Vienna,
Austria
Department of Dermatology,
Medical University of Vienna,
Vienna,
Austria
7 Unit of Dermatology,
Institut du Cancer-HCL,
Centre de recherché ne Cancérologie de Lyon,
Université Claude Bernard Lyon 1,
Lyon,
France
Institut du Cancer-HCL,
Centre de recherché ne Cancérologie de Lyon,
Université Claude Bernard Lyon 1,
Lyon,
France
8 Department of Dermatology,
Hospital Universitari de Bellvitge. IDIBELL. Barcelona University. Barcelona,
Spain
Hospital Universitari de Bellvitge. IDIBELL. Barcelona University. Barcelona,
Spain
13 Department of Oncology- Beatson West of Scotland Cancer Centre - Gartnavel General Hospital, Glasgow, UK
14 Department Dermatology Leiden University Medical Centre Leiden,
the Netherlands
the Netherlands
* Reprints
- Mots-clés : cutaneous T-cell lymphoma, maintenance treatment, randomized trial, lenalinomide, anti-angiogenic
- DOI : 10.1684/ejd.2017.3008
- Page(s) : 286-94
- Année de parution : 2017
EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs).